What is Pfizer?
Pharmaceuticals and vaccines company with $62.6B 2025 revenue scale and public-market buying capacity.
- Category
- Pharmaceuticals and vaccines
- Headquarters
- New York, NY
- Founded
- 1849
- Employees
- 81,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: PFE; Public company
What is Pfizer?
Pfizer is a public pharmaceuticals and vaccines company headquartered in New York, NY. Pfizer reported full-year 2025 revenues of $62.6 billion and reaffirmed 2026 revenue guidance of $59.5 billion to $62.5 billion.
Pfizer operates in pharmaceuticals and vaccines with a portfolio that includes Oncology medicines, Vaccines, Anti-infectives, Internal medicine. Pfizer reported full-year 2025 revenues of $62.6 billion and reaffirmed 2026 revenue guidance of $59.5 billion to $62.5 billion. The company employs about 81,000+ and trades as NYSE: PFE, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Pfizer through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Pfizer is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Pfizer offer?
Pfizer offers products and services across Oncology medicines, Vaccines, Anti-infectives, Internal medicine and related healthcare workflows.
- Oncology medicines· Therapeutics
- Vaccines· Vaccines
- Anti-infectives· Therapeutics
- Internal medicine· Therapeutics
- Inflammation and immunology· Therapeutics
- Rare disease· Therapeutics
- Hospital products· Provider channel
How does Pfizer make money?
Pfizer earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Pfizer earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $62.6B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Pfizer improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Pfizer?
Pfizer is led by Albert Bourla, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Albert BourlaChairman and Chief Executive OfficerCEO since 2019Leads Pfizer through post-COVID portfolio repositioning and oncology expansion.
- David DentonChief Financial Officer and Executive Vice PresidentCFO since 2022Oversees capital allocation, margin programs, and financial planning.
- Chris BoshoffChief Scientific Officer and President, Research and DevelopmentCSO in 2026Runs R&D strategy across oncology, immunology, vaccines, and internal medicine.
- Aamir MalikChief U.S. Commercial Officer and Executive Vice PresidentCommercial leader in 2026Leads U.S. commercialization and market access execution.
How do you contact Pfizer's leadership?
Pfizer publishes official investor-relations and media contact routes published by Pfizer, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official investor-relations and media contact routes published by Pfizer; personal executive email format not verified- Albert BourlaChairman and Chief Executive Officerofficial investor-relations and media contact routes published by Pfizer
- David DentonChief Financial Officer and Executive Vice Presidentofficial investor-relations and media contact routes published by Pfizer
- Chris BoshoffChief Scientific Officer and President, Research and Developmentofficial investor-relations and media contact routes published by Pfizer
Sources:Pfizer contactPfizer leadership
How much funding has Pfizer raised?
Pfizer is a mature public company, not a venture-backed startup. It trades as NYSE: PFE and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Pfizer's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is NYSE: PFE, $62.6B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Pfizer has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Pfizer get here?
Pfizer grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1849Pfizer foundedCharles Pfizer and Charles Erhart start the company in Brooklyn.
- 1940sPenicillin scale-upPfizer becomes a major antibiotics manufacturer.
- 2020COVID-19 vaccine authorizationPfizer and BioNTech bring Comirnaty to market at pandemic scale.
- 2023Seagen acquisitionPfizer expands oncology through the Seagen acquisition.
- 2025$62.6B revenuePfizer reports full-year 2025 revenues of $62.6 billion.
- 2026Guidance reaffirmedPfizer guides to $59.5 billion to $62.5 billion of 2026 revenue.
Who are Pfizer's competitors?
Pfizer competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- Merck & Co.Competes across oncology, vaccines, hospital products, and global pharma procurement.
- Bristol Myers SquibbOverlaps in oncology, hematology, immunology, and specialty-medicine budgets.
- Johnson & JohnsonCompetes in immunology, oncology, medtech-adjacent hospital relationships, and consumer/provider scale.
- NovartisCompetes in specialty medicines, oncology, cardiovascular, and global market access.
- RocheCompetes in oncology, diagnostics-linked therapeutics, immunology, and global hospital channels.
- AstraZenecaCompetes in oncology, respiratory, cardiovascular, vaccines, and global R&D intensity.
Pfizer — frequently asked questions
